Advertisement

Ascites

  • RamóN Bataller
  • Vicente Arroyo
  • Gilles Pomier-Layrargues
  • Ziad Hassoun
  • Dominique Franco
  • Sheila Sherlock

Abstract

In patients with cirrhosis and ascites, upright posture markedly activates sodiumretaining systems and impairs renal perfusion and sodium excretion [1]. Moreover, bed rest is associated with a greater response to diuretics in these patients [2]. For these reasons, bed rest has been traditionally recommended to cirrhotic patients with ascites. However no clinical trials have specifically addressed whether bed rest improves the management of ascites in cirrhotic patients. At present, we think that bed rest should be only recommended to patients with a poor response to diuretics or with an impaired renal function.

Keywords

Hepatic Encephalopathy Cirrhotic Patient Transjugular Intrahepatic Portosystemic Shunt Spontaneous Bacterial Peritonitis Refractory Ascites 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bernardi M, Santini C, Trevisani F, et al. (1985) Renal function impairment induced by change in posture in patients with cirrhosis and ascites. Gut 26:629–635PubMedCrossRefGoogle Scholar
  2. 2.
    Ring-Larsen H, Henriksen JH, Wilken C, et al. (1986) Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J 292:1351–1353CrossRefGoogle Scholar
  3. 3.
    Gauthier A, Levy VG, Quinton A, et al. (1986) Salt or not salt in the treatment of cirrhotic ascites: a randomised study. Gut 27:705–709PubMedCrossRefGoogle Scholar
  4. 4.
    Bernardi M, Laffi G, Salvagnini M, et al. (1993) Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 13:156–162PubMedGoogle Scholar
  5. 5.
    Pérez-Ayuso RM, Arroyo V, Planas R, et al. (1983) Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 84:961–968PubMedGoogle Scholar
  6. 6.
    Bataller R, Ginès P, Arroyo V (1997) Practical recommendations for the treatment of ascites and its complications. Drugs 54:571–580PubMedCrossRefGoogle Scholar
  7. 7.
    Arroyo V, Ginès P, Gerbes A, et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164–176PubMedCrossRefGoogle Scholar
  8. 8.
    Sherlock S, Senewiratne B, Scott A, et al. (1966) Complications of diuretic therapy in hepatic cirrhosis. Lancet 1:1049–1052PubMedCrossRefGoogle Scholar
  9. 9.
    Forns X, Ginès A, Ginès P, et al. (1994) The management of ascites and renal failure in cirrhosis. Semin Liver Dis 14:82–96PubMedCrossRefGoogle Scholar
  10. 10.
    Angeli P, Pria MD, De Bei E, et al. (1994) Randomized clinical study of the efficacy of amiloride and potassium canreonate in nonazotemic cirrhotic patients with ascites. Hepatology 19:72–79PubMedCrossRefGoogle Scholar
  11. 11.
    Lee FY, Lee SD, Tsai YT, et al. (1991) A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 12:236PubMedCrossRefGoogle Scholar
  12. 12.
    Angeli P, Albino G, Carraro P, et al. (1996) Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 23:264–270PubMedCrossRefGoogle Scholar
  13. 13.
    Ginès P, Arroyo V, Quintero E, et al. (1987) Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 93:234–241PubMedGoogle Scholar
  14. 14.
    Salerno F, Badalamenti S, Incerti P, et al. (1987) Repeated paracentesis and i.v. albumin infusion to treat “tense” ascites in cirrhotic patients: a safe alternative therapy. J Hepatol 5:102–108PubMedCrossRefGoogle Scholar
  15. 15.
    Fernândez-Esparrach G, Guevara M, Sort P, et al. (1997) Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 26:614–620PubMedCrossRefGoogle Scholar
  16. 16.
    Ginès P, Titó LI, Arroyo V, et al. (1988) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94:1493–1502PubMedGoogle Scholar
  17. 17.
    Pozzi M, Osculati G, Boari G, et al. (1994) Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 106:709–719PubMedGoogle Scholar
  18. 18.
    Ginès A, Fernández-Esparrach G, Monescillo A, et al. (1996) Randomized trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111:1002–1010PubMedCrossRefGoogle Scholar
  19. 19.
    Saló J, Ginès A, Ginès P, et al. (1997) Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 27:645–653PubMedCrossRefGoogle Scholar
  20. 20.
    Ruiz del Arbol L, Monescillo A, Jiménez W, et al. (1997) Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113:579–587PubMedCrossRefGoogle Scholar
  21. 21.
    Ginès P, Berl T, Bernardi M, et al. (1998) Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 28:851–864PubMedCrossRefGoogle Scholar
  22. 22.
    Gerbes AL, Guelberg V, Grosshadern C (1999) VPA-895, an orally active vasopressin receptor antagonist, improves hyponatremia in patients with cirrhosis. A double-blind placebo controlled multicenter trial. Hepatology 30:419ACrossRefGoogle Scholar

References

  1. 1.
    Olafson S, Blei AT (1995) Diagnosis and management of ascites in the age of TIPS. Am J Roentgenol 165:9–15Google Scholar
  2. 2.
    Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, Hoyos M, Viladomiu L, Rimola A, Morillas R, Salmeron JM, Gines A, Esteban R, Rodes J (1991) Paracentesis with intravenous infusions of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 325:829–835PubMedCrossRefGoogle Scholar
  3. 3.
    Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JL, Allen MJ, Baum RA, Gadacz TR, Camara DS, Caruana JA, Schiff ER, Livingstone AS, Samanta AK, Najeh AZ, Glick ME, Juler GL, Adham N, Baker JD, Cain GD, Jordan PH, Wolf DC, Fulenwider JT, James KE, and the Veterans Administration Cooperative Study on the Treatment of Alcoholic Cirrhosis with Ascites (1989) Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 321:1632–1638PubMedCrossRefGoogle Scholar
  4. 4.
    Welch HF, Welch CS, Carter JH (1964) Prognosis after surgical treatment of ascites. Results of side-to-side shunt in 40 patients. Surgery 56:75–82PubMedGoogle Scholar
  5. 5.
    Franco D, Vons C, Traynor O, Smajda C (1988) Should portosystemic shunt be reconsidered in the treatment of untractable ascites in cirrhosis? Arch Surg 123:987–991PubMedCrossRefGoogle Scholar
  6. 6.
    Schiffman ML, Jeffers L, Hoofnagle JH, Tralka TS (1995) The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 22:1591–1597CrossRefGoogle Scholar
  7. 7.
    Ferrai HS, Bjarnason H, Wegryn SA, Rengel GJ, Mazarian GK, Rank JM, Tadavarthy SM, Hunter DW, Castaneda-Zuniga WR (1993) Refractory ascites: early experience in treatment with transjugular intrahepatic portosystemic shunt. Radiology 189:795–801Google Scholar
  8. 8.
    Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villareal L, Zozaya JM, Betes M, Herrero JI, Prieto J (1995) Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 21:986–994PubMedGoogle Scholar
  9. 9.
    Somberg KA, Lake JR, Tomlanovich J, Laberge JM, Feldstein V, Bass N (1995) Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 21:709–716PubMedGoogle Scholar
  10. 10.
    Ochs A, Rossle M, Haag K, Hauenstein KH, Beibert P, Siegerstetter V, Huokner M, Langer M, Blum HE (1995) The transjugular intrahepatic portosytemic stent-shunt procedure for refractory ascites. N Engl J Med 332:1193–1197CrossRefGoogle Scholar
  11. 11.
    Forrest EH, Stanley AJ, Redhead DN, McGilchrist AJ, Hayes PC (1996) Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Aliment Pharmacol Ther 10:801–806PubMedCrossRefGoogle Scholar
  12. 12.
    Deschênes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, Lafortune M, Pomier-Layrargues G (1999) Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 94:1361–1365PubMedGoogle Scholar
  13. 13.
    Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger J, and a French group of clinicians and a group of biologists (1996) Transjugular intrahepatic portosystemic shunts: comparison with parecentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 25:135–144PubMedCrossRefGoogle Scholar
  14. 14.
    Martinet JP, Legault L, Cernacek P, Roy L, Dufresne MP, Spahr L, Fenyves D, Pomier-Layrargues G (1996) Changes in plasma endothelin 1 and big endothelin 1 induced by transjugular intrahepatic shunt in cirrhotic patients with refractory ascites. J Hepatol 25:700–706PubMedCrossRefGoogle Scholar
  15. 15.
    Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L (1995) Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122:816–822PubMedGoogle Scholar
  16. 16.
    Ochs A, Gerbes AL, Haag K, Holl J, Hauenstein KH, Waggershausen T, Reiser M, Paumgartner G, Blum HE, Rossle M (1995) TIPS and paracentesis in the treatment of refractory ascites (RA): interim analysis of a randomized controlled trial (abstract). Hepatology 22 (no. 4, part 2):297AGoogle Scholar
  17. 17.
    Hauenstein KH, Haag K, Ochs A, Langer M, Rossle M (1995) The reducing stent: treatment for transjugular intrahepatic portosystemic shunt induced refractory hepatic encephalopathy and liver failure. Radiology 194:175–179PubMedGoogle Scholar
  18. 18.
    Fenyves D, Dufresne MP, Raymond J, Lafortune M, Willems B, Pomier-Layrargues G (1994) Successful reversal of chronic incapacitating post-TIPS encephalopathy by balloon occlusion of the stent. Can J Gastroenterol 8:75–80Google Scholar

References

  1. 1.
    Barker HG, Reemtsma K (1960) The portacaval shunt operation in patients with cirrhosis and ascites. Surgery 48:142–154PubMedGoogle Scholar
  2. 2.
    Welch HF, Welch CS, Carter JH (1964) Prognosis after surgical treatment of ascites: results of side-to-side shunt in 40 patients. Surgery 56:75–82PubMedGoogle Scholar
  3. 3.
    Burchell AR, Rousselot LM, Panke WF (1968) A seven-year experience with side-to-side portacaval shunt for cirrhotic ascites. Ann Surg 168:655–670PubMedCrossRefGoogle Scholar
  4. 4.
    Welch CS, Attarian E, Welch HF (1958) The treatment of ascites by side-to-side portacaval shunt. Bull NY Acad Med 34:249–255Google Scholar
  5. 5.
    Orloff MJ (1970) Pathogenesis and surgical treatment of intractable ascites associated with alcoholic cirrhosis. Ann NY Acad Sci 170:213–238CrossRefGoogle Scholar
  6. 6.
    Franco D, Vons C, Traynor O, Smadja C (1988) Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis ? Arch Surg 123:987–991PubMedCrossRefGoogle Scholar
  7. 7.
    Orloff MJ, Orloff MS, Orloff SL, Girard B (1997) Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites. J Am Coll Surg 184:557–570PubMedGoogle Scholar
  8. 8.
    Leveen HH, Christoudias G, Moon IP, Luft R, Falk G, Grosberg S (1974) Peritoneovenous shunting for ascites. Ann Surg 180:580–591PubMedCrossRefGoogle Scholar
  9. 9.
    Blendis LM, Greig PD, Langer B, Baigrie RS, Ruse J, Taylor BR (1979) The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites. Gastroenterology 77:250–257PubMedGoogle Scholar
  10. 10.
    Vons C, Hadengue A, Lee SS, Smadja C, Franco D, Lebrec D (1991) Splanchnic and systemic hemodynamics in cirrhotic patients with refractory ascites. Effect of peritoneovenous shunting. HPB Surg 3:259–269PubMedCrossRefGoogle Scholar
  11. 11.
    Ragni MV, Lewis JH, Spero JA (1983) Ascites-induced LeVeen shunt coagulopathy. Ann Surg 198:91–95PubMedCrossRefGoogle Scholar
  12. 12.
    Darsee JR, Fulenwider JT, Rikkers LF, et al. (1981) Hemodynamics of LeVeen shunt pulmonary edema. Ann Surg 194:189–192PubMedCrossRefGoogle Scholar
  13. 13.
    Smadja C, Franco D (1985) The LeVeen shunt in the elective treatment of intractable ascites in cirrhosis. A prospective study on 140 patients. Ann Surg 201:488–496PubMedCrossRefGoogle Scholar
  14. 14.
    Moskovitz M (1990) The peritoneovenous shunt: expectations and reality. Am J Gastroenterol 85:917–929PubMedGoogle Scholar
  15. 15.
    Zervos EE, McCormick J, Goode SE, Rosemurgy AS (1997) Peritoneovenous shunts in patients with intractable ascites: palliation at what price? Am Surg 63:157–162PubMedGoogle Scholar
  16. 16.
    Prokesch RC, Rimland D (1983) Infectious complications of the peritoneovenous shunt. Am J Gastroenterol 78:235–240PubMedGoogle Scholar
  17. 17.
    Smadja C, Tridard D, Franco D (1986) Recurrent ascites due to central venous thrombosis after peritoneojugular (LeVeen) shunt. Surgery 100:535–540PubMedGoogle Scholar
  18. 18.
    Schwartzentruber DJ, Leapnan SB, Filo RS, Madura JA (1987) Thrombofibrinous sheath occlusion of peritoneovenous shunts. Surgery 102:534–539PubMedGoogle Scholar
  19. 19.
    Eckhauser FE, Strodel WE, Knol JA, Turcotte JG (1979) Superior vena caval obstruction associated with long-term peritoneovenous shunting. Ann Surg 190:758–760PubMedCrossRefGoogle Scholar
  20. 20.
    Stanley MM, Reyes CV, Greenlee HB, Nemchausky B, Reinhardt GF (1996) Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites. An autopsy study with clinical correlations. Dig Dis Sci 41:571–577PubMedCrossRefGoogle Scholar
  21. 21.
    Fulenwider JT, Galambos JD, Smith RB, Henderson JM, Warren WD (1986) LeVeen vs. Denver peritoneovenous shunts for intractable ascites in cirrhosis. Arch Surg 121:351–355PubMedCrossRefGoogle Scholar
  22. 22.
    Wapnick S, Grosberg SJ, Evans MI (1979) Randomized prospective matched pair study comparing peritoneovenous shunt and conventional therapy in massive ascites. Br J Surg 66:667–670PubMedCrossRefGoogle Scholar
  23. 23.
    Bories P, Garcia-Compean D, Michel H, et al. (1986) The treatment of refractory ascites by the LeVeen shunt: a multi-centre controlled trial (57 patients). J Hepatol 3:212–218PubMedCrossRefGoogle Scholar
  24. 24.
    Stanley MM, Ochi S, Lee KK, et al. (1989) Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 321:1632–1638PubMedCrossRefGoogle Scholar
  25. 25.
    Ring-Larsen H, Siemssen O, Krintel JJ, Stadager C, Henriksen JH (1989) Denver shunt in the treatment of refractory ascites in cirrhosis. A randomized control trial. Gastroenterology 96:A649Google Scholar
  26. 26.
    Gines P, Arroyo V, Vargas V, et al. (1991) Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 325:829–835PubMedCrossRefGoogle Scholar
  27. 27.
    Gines A, Planas R, Angeli P, et al. (1995) Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. Hepatology 22:124–131PubMedGoogle Scholar
  28. 28.
    Hillaire S, Labianca M, Smadja C, Grange D, Franco D (1998) La dérivation péritonéoveineuse dans la cirrhose: résultats d’une étude prospective sur les facteurs d’amélioration du pronostic. Gastroentérol Clin Biol 12:681–686Google Scholar
  29. 29.
    Meakins JL, Hillaire S, Vons C, Smadja C, Franco D (1989) Perioperative antibiotics (two doses) control early but not late infectious complications of peritoneovenous shunt. Surg Res Commun 5:55–58Google Scholar
  30. 30.
    Hillaire S, Labianca M, Borgonovo G, Smadja C, Grange D, Franco D (1993) Peritoneovenous shunting of intractable ascites in cirrhotic patients: improving results and predictive factors of failure. Surgery 113:373–379PubMedGoogle Scholar
  31. 31.
    Guardiola J, Xiol W, Escriba JM, et al. (1995) Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt. Am I Gastroenterol 90:2097–2102Google Scholar
  32. 32.
    Franco D, Labianca M, Smadja C, Fragoso J (1998) A titanium catheter tip for peritoneovenous shunts. Artif Organs 12:81–82CrossRefGoogle Scholar
  33. 33.
    Franco D, Charra M, Jeambrun P, Belghiti J, Cortesse A, Sossler C (1983) Nutrition and immunity after peritoneovenous drainage of intractable ascites in cirrhotic patients. Am J Surg 146:652–657PubMedCrossRefGoogle Scholar
  34. 34.
    Blendis LM, Harrison JE, Russel DM, et al. (1986) Effects of peritoneovenous shunting on body composition. Gastroenterology 90:127–134PubMedGoogle Scholar
  35. 35.
    Franco D, Meakins JL, Wu A, et al. (1989) Long-term results (>5 years) in patients with peritoneovenous shunting for intractable ascites: liver function and cancer mortality. HPB Surg 1:185–194PubMedCrossRefGoogle Scholar
  36. 36.
    Poynard T, Naveau S, Doffoel M, et al. (1999) Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J Hepatol 30:1130–1137PubMedCrossRefGoogle Scholar
  37. 37.
    Yiou R, Vons C, Franco D (1997) Traitement de l'hydrothorax du cirrhotique par une valve de dérivation pleuro-péritonéale. Gastroentérol Clin Biol 20:1135Google Scholar
  38. 38.
    Montanari M, Orsi P, Pugliano G (1996) Hepatic hydrothorax without diaphragmatic defect. An original surgical treatment. J Cardiovasc Surg 37:425–427Google Scholar
  39. 39.
    Vadeyar HJ, Doran JD, Charnley R, Ryder SD (1999) Saphenoperitoneal shunts for patients with intractable ascites associated with chronic liver disease. Br J Surg 86:882–885PubMedCrossRefGoogle Scholar

References

  1. 1.
    Gerbes AL, Guelberg V, Grosshadren C (1999) VPA-895, an orally active Vasopressin receptor antagonist, improves hyponatremia in patients with cirrhosis. A double-blind placebo controlled multicenter trial. Hepatology 30-.419ACrossRefGoogle Scholar
  2. 2.
    Runyon BA (1998) Management of adult patients with ascites caused by cirrhosis. Hepatology 27:264–272PubMedCrossRefGoogle Scholar
  3. 3.
    Sort P, Navasa M, Arroyo V, et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341:403–409PubMedCrossRefGoogle Scholar
  4. 4.
    Goulis J, Patch D, Burroughs AK (1999) Bacterial infection in the pathogenesis of variceal bleeding. Lancet 353:139–142PubMedCrossRefGoogle Scholar
  5. 5.
    Aparicio JR, Such J, Pascual S, et al. (1999) Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 31:277–283PubMedCrossRefGoogle Scholar
  6. 6.
    Wong F, Blendis L (1995) Transjugular intrahepatic portosystemic shunt for refractory ascites: tipping the sodium balance. Hepatology 22:358–364PubMedCrossRefGoogle Scholar
  7. 7.
    Orloff MJ, Orloff MS, Orloff SL, et al. (1997) Experimental, clinical and metabolic results of side-to-side porta-caval shunt for intractable cirrhotic ascites. J Am Coll Surg 184:557–570PubMedGoogle Scholar
  8. 8.
    Le Veen HH, Christoudias G, Moon IP, et al. (1974) Peritoneovenous shunting for ascites. Ann Surg 180:580–591CrossRefGoogle Scholar

References

  1. 1.
    Adam R, Bismuth H (1997) The role of hepatic transplantation — the French view. In: Schein M, Wise L (eds) Crucial controversies in surgery. Karger Landes Systems, Basel, p 159Google Scholar
  2. 2.
    Knechte SJ, Rikkers LF (1997) The role of hepatic transplantation — the American view. In: Schein M, Wise L (eds) Crucial controversies in surgery. Karger Landes Systems, Basel, p 166Google Scholar
  3. 3.
    Schein M, Wittmann DH, Aprahamian CC, Condon RE (1995) The abdominal compartment syndrome: the physiological and clinical consequences of elevated intra-abdominal pressure. J Am Coll Surg 180:745–753PubMedGoogle Scholar
  4. 4.
    Savino JA, Cerabona T, Agarwal N, Byrne D (1988) Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function. Ann Surg 208:504–511PubMedCrossRefGoogle Scholar
  5. 5.
    Luca A, Cirera I, Garcia-Pagan JC, Feu F, Pizcueta P, Bosch J, Rodes J (1993) Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. Gastroenterology 104:222–227PubMedGoogle Scholar
  6. 6.
    Rossle M, Ochs A, Gulberg V, et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342:1701–1707PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • RamóN Bataller
  • Vicente Arroyo
  • Gilles Pomier-Layrargues
  • Ziad Hassoun
  • Dominique Franco
  • Sheila Sherlock

There are no affiliations available

Personalised recommendations